SubsidieMeestersIOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Projectdetails
Introduction
Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent unmet medical need.
Project Overview
Our project stands for industrializing our analytically validated multiplexed protein-function based biomarker assay (IOO), currently at TRL6. This assay is based on our proprietary bio-imaging technology.
Clinical Validation
Whilst scientifically validated, we need further clinical validation to obtain increased datasets required for regulatory certification for clinical deployment.
Potential Impact
This assay could triple the efficacy of currently available immune-oncology treatments by accurately predicting patient response to immune checkpoint inhibitors, which are the basis of 90% of current immuno-oncology therapies.
Future Goals
If successful, we will bring this transformative solution to hospitals worldwide. The upshot could be game-changing: doubling survival rates for high-prevalence, lethal tumors like lung cancer.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.496.112 |
| Totale projectbegroting | € 3.565.875 |
Tijdlijn
| Startdatum | 1-8-2024 |
| Einddatum | 31-7-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FASTBASE SOLUTIONS SOCIEDAD LIMITADApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
canceR agnOstic immUnoTherapy predIctioN blood-tEstPamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment. | EIC Accelerator | € 2.500.000 | 2023 | Details |
IntraVenous Immune BoostHEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
canceR agnOstic immUnoTherapy predIctioN blood-tEst
PamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment.
IntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry testThe project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs). | ERC Proof of... | € 150.000 | 2022 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Precision Diagnostics for Predicting Therapy Response to Bispecific AntibodiesThis project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia. | ERC Proof of... | € 150.000 | 2025 | Details |
Trial BoosterVitroScan en Imuno ontwikkelen een screeningsplatform om de effectiviteit van immuuntherapie bij blaaskanker te voorspellen, waardoor patiëntselectie voor klinische studies verbetert. | Mkb-innovati... | € 347.410 | 2022 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
The development of a predictive biomarker for immunotherapy outcome based on flow cytometry test
The project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs).
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
Precision Diagnostics for Predicting Therapy Response to Bispecific Antibodies
This project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia.
Trial Booster
VitroScan en Imuno ontwikkelen een screeningsplatform om de effectiviteit van immuuntherapie bij blaaskanker te voorspellen, waardoor patiëntselectie voor klinische studies verbetert.